Streetbeat News

Revenues

BNGO

Bionano Genomics has revised its 2024 revenue guidance to $36M-$40M, down from the previous $37M-$41M, and below the $38.08M consensus. The company also expects Q3 2024 revenue to be $7.9M-$8.9M, significantly lower than the $10.09M consensus.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 7:16 am

EQX

Equinox Gold (AMEX:EQX) reported Q2 2024 adjusted EPS of $(0.01), meeting analyst expectations, but missed sales estimates with $269.4 million, a 0.80% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 7:04 am

GOOG

GOOGL

YouTube Shorts, Google's (NASDAQ:GOOG) (NASDAQ:GOOGL) short-form video platform, has reached 1 trillion views in India. CEO Neal Mohan announced this milestone at the YouTube Brandcast event in New Delhi, highlighting the platform's immense popularity and the flourishing creator community in India.

Portfolio Pulse from Ananthu C U

August 08, 2024 | 6:59 am

BMY

EVO

Evotec SE has advanced its strategic neuroscience partnership with Bristol Myers Squibb, earning a $25 million milestone payment. This progress enhances their joint pipeline of advanced neuroscience programs aimed at neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:35 am

CRH

CRH has raised its 2024 outlook, now expecting EPS of $5.40-$5.60 (previously $5.15-$5.45) and adjusted EBITDA of $6.82B-$7.02B (previously $6.55B-$6.85B). The company cites strong financial performance, positive business momentum, and recent portfolio activity as reasons for the improved guidance.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:13 am

CRH

CRH (NYSE:CRH) reported Q2 earnings per share (EPS) of $1.88, a 16.05% increase from $1.62 YoY. Sales were $9.65 billion, a slight decrease from $9.71 billion YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:09 am

VRTX

Vertex Pharmaceuticals has secured NHS England reimbursement for its CASGEVY therapy, which treats transfusion-dependent beta thalassemia (TDT). This therapy is one of the first to be funded by NHS England's Innovative Medicines Fund, allowing eligible TDT patients in England to access it immediately.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:00 am

PGEN

Precigen has priced a $30 million public offering of 35,294,118 common stock at $0.85 per share. The proceeds will be used for advancing PRGN-2012 to regulatory approval, limited clinical development of other pipeline assets, and general corporate purposes. The funds, along with strategic reprioritization and existing cash, are expected to support operations into early 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 5:43 am

BETR

Better Home & Finance reported Q2 sales of $31.41 million and a net loss of $42.21 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 5:38 am

FSM

Fortuna Silver Mines (NYSE:FSM) reported Q2 2024 earnings of $0.10 per share, missing the analyst consensus estimate of $0.15 by 33.33%. However, the company saw a significant increase in sales, reporting $259.971 million, up 64.12% from $158.400 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 5:34 am